# Design Therapeutics, Inc.: financial statements, quarterly

DSGN · Nasdaq · CIK 1807120 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dsgn.md) · [Financials](/companies/dsgn/financials.md) · [Filings](/companies/dsgn/filings.md) · [Insiders](/companies/dsgn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dsgn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0000950170-25-065643.md) | [0.0 d](/filings/0000950170-25-105062.md) | [0.0 d](/filings/0001193125-25-266970.md) | [0.0 d](/filings/0001193125-26-098491.md) | [0.0](/filings/0001193125-26-187063.md) | [0.0 d](/filings/0001193125-26-329579.md) |
| Research and development | $m | [13.3](/filings/0000950170-24-123349.md) | [11.0 d](/filings/0000950170-25-035910.md) | [9.8](/filings/0000950170-25-065643.md) | [10.5](/filings/0000950170-25-105062.md) | [11.9](/filings/0001193125-25-266970.md) | [12.2 d](/filings/0001193125-26-098491.md) | [15.4](/filings/0001193125-26-187063.md) | [15.7](/filings/0001193125-26-329579.md) | [14.6](/filings/0001193125-25-266970.md) | [13.4 d](/filings/0001193125-26-098491.md) | [14.4](/filings/0001193125-26-187063.md) | [16.4](/filings/0001193125-26-329579.md) |
| Operating income | $m | [(18.8)](/filings/0000950170-24-123349.md) | [(15.1) d](/filings/0000950170-25-035910.md) | [(14.4)](/filings/0000950170-25-065643.md) | [(15.0)](/filings/0000950170-25-105062.md) | [(16.2)](/filings/0001193125-25-266970.md) | [(16.7) d](/filings/0001193125-26-098491.md) | [(20.4)](/filings/0001193125-26-187063.md) | [(21.6)](/filings/0001193125-26-329579.md) | [(19.3)](/filings/0001193125-25-266970.md) | [(18.2) d](/filings/0001193125-26-098491.md) | [(19.7)](/filings/0001193125-26-187063.md) | [(22.2)](/filings/0001193125-26-329579.md) |
| Net income | $m | [(15.8)](/filings/0000950170-24-123349.md) | [(11.8) d](/filings/0000950170-25-035910.md) | [(11.1)](/filings/0000950170-25-065643.md) | [(11.8)](/filings/0000950170-25-105062.md) | [(13.0)](/filings/0001193125-25-266970.md) | [(13.7) d](/filings/0001193125-26-098491.md) | [(17.7)](/filings/0001193125-26-187063.md) | [(19.1)](/filings/0001193125-26-329579.md) | [(17.0)](/filings/0001193125-25-266970.md) | [(16.0) d](/filings/0001193125-26-098491.md) | [(17.6)](/filings/0001193125-26-187063.md) | [(20.2)](/filings/0001193125-26-329579.md) |
| Diluted EPS | $ per share | [(0.28)](/filings/0000950170-24-123349.md) | not reported | [(0.20)](/filings/0000950170-25-065643.md) | [(0.21)](/filings/0000950170-25-105062.md) | [(0.23)](/filings/0001193125-25-266970.md) | not reported | [(0.31)](/filings/0001193125-26-187063.md) | [(0.34)](/filings/0001193125-26-329579.md) | [(0.30)](/filings/0001193125-25-266970.md) | not reported | [(0.29)](/filings/0001193125-26-187063.md) | [(0.32)](/filings/0001193125-26-329579.md) |
| Basic EPS | $ per share | [(0.28)](/filings/0000950170-24-123349.md) | not reported | [(0.20)](/filings/0000950170-25-065643.md) | [(0.21)](/filings/0000950170-25-105062.md) | [(0.23)](/filings/0001193125-25-266970.md) | not reported | [(0.31)](/filings/0001193125-26-187063.md) | [(0.34)](/filings/0001193125-26-329579.md) | [(0.30)](/filings/0001193125-25-266970.md) | not reported | [(0.29)](/filings/0001193125-26-187063.md) | [(0.32)](/filings/0001193125-26-329579.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [27.9](/filings/0000950170-23-062958.md) | [21.2](/filings/0000950170-25-035910.md) | [29.4](/filings/0000950170-24-055788.md) | [45.7](/filings/0000950170-24-090337.md) | [30.3](/filings/0000950170-24-123349.md) | [22.6](/filings/0001193125-26-098491.md) | [13.7](/filings/0000950170-25-065643.md) | [19.7](/filings/0000950170-25-105062.md) | [15.1](/filings/0001193125-25-266970.md) | [16.9](/filings/0001193125-26-329579.md) | [12.8](/filings/0001193125-26-187063.md) | [12.9](/filings/0001193125-26-329579.md) |
| Current assets | $m | [295](/filings/0000950170-23-062958.md) | [285](/filings/0000950170-25-035910.md) | [274](/filings/0000950170-24-055788.md) | [265](/filings/0000950170-24-090337.md) | [257](/filings/0000950170-24-123349.md) | [248](/filings/0001193125-26-098491.md) | [234](/filings/0000950170-25-065643.md) | [220](/filings/0000950170-25-105062.md) | [209](/filings/0001193125-25-266970.md) | [224](/filings/0001193125-26-329579.md) | [227](/filings/0001193125-26-187063.md) | [212](/filings/0001193125-26-329579.md) |
| Total assets | $m | [300](/filings/0000950170-23-062958.md) | [290](/filings/0000950170-25-035910.md) | [279](/filings/0000950170-24-055788.md) | [270](/filings/0000950170-24-090337.md) | [262](/filings/0000950170-24-123349.md) | [252](/filings/0001193125-26-098491.md) | [237](/filings/0000950170-25-065643.md) | [223](/filings/0000950170-25-105062.md) | [212](/filings/0001193125-25-266970.md) | [226](/filings/0001193125-26-329579.md) | [230](/filings/0001193125-26-187063.md) | [215](/filings/0001193125-26-329579.md) |
| Current liabilities | $m | [12.4](/filings/0000950170-23-062958.md) | [9.6](/filings/0000950170-25-035910.md) | [7.1](/filings/0000950170-24-055788.md) | [6.4](/filings/0000950170-24-090337.md) | [7.4](/filings/0000950170-24-123349.md) | [8.5](/filings/0001193125-26-098491.md) | [8.2](/filings/0000950170-25-065643.md) | [8.7](/filings/0000950170-25-105062.md) | [11.2](/filings/0001193125-25-266970.md) | [13.1](/filings/0001193125-26-329579.md) | [10.2](/filings/0001193125-26-187063.md) | [11.2](/filings/0001193125-26-329579.md) |
| Total liabilities | $m | [14.9](/filings/0000950170-23-062958.md) | [12.0](/filings/0000950170-25-035910.md) | [9.2](/filings/0000950170-24-055788.md) | [8.3](/filings/0000950170-24-090337.md) | [9.2](/filings/0000950170-24-123349.md) | [10.0](/filings/0001193125-26-098491.md) | [9.6](/filings/0000950170-25-065643.md) | [9.8](/filings/0000950170-25-105062.md) | [12.1](/filings/0001193125-25-266970.md) | [13.7](/filings/0001193125-26-329579.md) | [12.4](/filings/0001193125-26-187063.md) | [13.3](/filings/0001193125-26-329579.md) |
| Shareholders' equity | $m | [285](/filings/0000950170-24-123349.md) | [278](/filings/0001193125-26-098491.md) | [270](/filings/0000950170-25-105062.md) | [261](/filings/0001193125-25-266970.md) | [252](/filings/0001193125-25-266970.md) | [242](/filings/0001193125-26-329579.md) | [228](/filings/0001193125-26-329579.md) | [213](/filings/0001193125-26-329579.md) | [200](/filings/0001193125-25-266970.md) | [213](/filings/0001193125-26-329579.md) | [218](/filings/0001193125-26-329579.md) | [202](/filings/0001193125-26-329579.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(14.5) d](/filings/0000950170-24-123349.md) | [(12.8) d](/filings/0000950170-25-035910.md) | [(12.4)](/filings/0000950170-25-065643.md) | [(11.3) d](/filings/0000950170-25-105062.md) | [(9.5) d](/filings/0001193125-25-266970.md) | [(9.9) d](/filings/0001193125-26-098491.md) | [(16.8)](/filings/0001193125-26-187063.md) | [(14.4) d](/filings/0001193125-26-329579.md) | [(11.2) d](/filings/0001193125-25-266970.md) | [(12.0) d](/filings/0001193125-26-098491.md) | [(16.4)](/filings/0001193125-26-187063.md) | [(15.5) d](/filings/0001193125-26-329579.md) |
| Capital expenditure | $m | [0.1 d](/filings/0000950170-24-123349.md) | [0.0 d](/filings/0000950170-25-035910.md) | [0.2](/filings/0000950170-25-065643.md) | [0.2 d](/filings/0000950170-25-105062.md) | [(0.0) d](/filings/0001193125-25-266970.md) | [0.0 d](/filings/0001193125-26-098491.md) | [0.1](/filings/0001193125-26-187063.md) | [0.1 d](/filings/0001193125-26-329579.md) | [0.0 d](/filings/0001193125-25-266970.md) | [0.0 d](/filings/0001193125-26-098491.md) | [0.0](/filings/0001193125-26-187063.md) | [0.0 d](/filings/0001193125-26-329579.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [55.8](/filings/0000950170-23-062958.md) | [55.9](/filings/0000950170-24-055788.md) | [55.9](/filings/0000950170-24-090337.md) | [56.0](/filings/0000950170-24-123349.md) | [56.5](/filings/0000950170-25-065643.md) | [56.6](/filings/0000950170-25-105062.md) | [56.6](/filings/0001193125-25-266970.md) | [56.8](/filings/0001193125-26-187063.md) | [56.9](/filings/0001193125-26-329579.md) | [57.0](/filings/0001193125-25-266970.md) | [61.4](/filings/0001193125-26-187063.md) | [62.5](/filings/0001193125-26-329579.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 62,581,651 at 2026-07-29, from the cover of the [10-Q filed 2026-08-03](/filings/0001193125-26-329579.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.